

## Invitation to the guest lecture

of

### Kirsten Nørgaard

Associate Professor, Specialist in Endocrinology and Internal Medicine,  
Dep.of Endocrinology, Hvidovre University Hospital, Denmark

**Monday, November 27<sup>th</sup>, 2017 – 01:30 PM**

Johannes Kepler University Linz, Science Park 1, 2<sup>nd</sup> Floor, Room 246

## **Treatment options for type 1 diabetes - is the addition of glucagon a possibility?**

**Abstract:** For 25 years it has been evident that strict metabolic control is the best way to decrease occurrence of diabetes late complications. However, it is not easy as hypoglycemia occur more frequently, when a low level of HbA1c is approached. The fear of hypoglycemia is for most patients a hinder for good metabolic control. Further, frequent hypoglycemic episodes add to the increasing weight in patients with type 1 diabetes.

Different approaches for treatment of type 1 diabetes with insulin and bolus calculation (injection therapy, insulin pump treatment) and closed-loop will be discussed. Glucagon is a hormone with potential to be included in the treatment together with insulin. The current knowledge on how glucagon can avoid and treat hypoglycemia and which limitations and benefits for including glucagon in the different treatment approaches will be dealt with



**Bio:** Dr. Kirsten Nørgaard is responsible for type 1 treatment and insulin pump treatment at Hvidovre University Hospital. She is also the leader of the hospital's outpatient diabetes clinic.

Dr. Nørgaard provides education for patients as well as health care professionals on diabetes in general and on insulin pump treatment and CGM use, both at the national and international level. She also participates in curriculum design at the local and national level.

Dr. Nørgaard has been involved in insulin pumps since the 1980s and was the author of a nationwide study on the use of CSII in Denmark in 2001, which actually was the start for changing insulin pump use in Denmark. She also participated in more multicenter studies in Europe on the use of CSII and CGM, and is a member on different European Advisory Boards for CSII. The use of bolus calculation and bolus calculators in different patient groups using insulin MDI treatment has also been a focus for the last years. She has published approx. 110 papers in scientific journals. In 2008, Dr. Nørgaard together with Danish Technical University established the DiaCon-collaboration for developing closed loop and other technical support solutions for diabetes treatment, some of them may include glucagon.